Meeting
2018 ASCO Annual Meeting
Phase II study of panitumumab, 5-fluorouracil, mitomycin-c and radiotherapy treatment in patients with non-metastatic squamous cell carcinoma of the anal canal: safety and efficacy results (VITAL study)—GEMCAD 09-02.
Authors
Jaime Feliu
Hospital Universitario La Paz, Madrid, Spain
Jaime Feliu , Rocio Garcia-Carbonero , Jaume Capdevila , Inmaculada Guasch , Vicente Alonso , Carlos López-López , Pilar Garcia Alfonso , Carmen Castañon Lopez , Isabel Sevilla , Joan Maurel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Anal Cancer
Clinical Trial Registration Number
NCT01285778
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3566)
DOI
10.1200/JCO.2018.36.15_suppl.3566
Abstract #
3566
Poster Bd #
59
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): Safety and preliminary efficacy results.
First Author: Madhur Garg
Poster
2020 Gastrointestinal Cancers Symposium
Post hoc safety and effectiveness analysis of aflibercept + FOLFIRI for patients with metastatic colorectal cancer (mCRC) previously treated with antiepidermal growth factor receptor (EGFR) therapy in OZONE.
First Author: Thomas H. Cartwright
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): Results from the randomized phase II RESGEX study.
First Author: Ulrich Keilholz